Table 1.

Pharmacological characterization of PF-00547659 in comparison with MECA-367

	PF-00547659	MECA-367
Antibody type	Human IgG2 kappa class	Rat IgG2a kappa class
Reactivity	Human and cynomolgus MAdCAM	Mouse MAdCAM
BIAcore binding to MAdCAM	hMAdCAM-IgG1 Fc fusion KD 16.1 pmol·L−1 (n = 5, CI = 7, 37.2)	mMAdCAM-IgG1 Fc fusion KD 5.1 pmol·L−1 (n = 2)
Inhibition of CHO-hMAdCAM binding to JY cells	IC50, 0.457 µg·mL−1 (n = 34; 95% CI = 0.405, 0.516).	N.D.
Inhibition of CHO-cynoMAdCAM to JY cells	IC50, 0.651 µg·mL−1 (n = 18, 95% CI = 0.566, 0.748)	N.D.
Inhibition of MAdCAM-IgG1 Fc fusion protein to JY cells	hMAdCAM-IgG1 Fc fusion IC50, 0.037 µg·mL−1 (n = 32; 95% CI = 0.027, 0.052)	mMAdCAM-IgG1 Fc fusion IC50, 0.033 µg·mL−1 (n = 4; 95% CI = 0.021, 0.05)
Inhibition of fibronectin and VCAM binding to Jurkat T-cells	IC50, >24.5 µg·mL−1	N.D.

MAdCAM, mucosal addressin cell adhesion molecule; N.D., not determined; VCAM, vascular cell adhesion molecule.